中国现代神经疾病杂志 ›› 2011, Vol. 11 ›› Issue (4): 408-412. doi: 10.3969/j.issn.1672-6731.2011.04.008

• 随机对照临床试验 • 上一篇    下一篇

2 唑尼沙胺添加治疗部分性癫痫的临床疗效及安全性:多中心随机双盲安慰剂对照研究

张丽娜,刘雅婧,丁成赟,史树贵,林卫红,陈涛,孙红斌,徐运,董万利,陈启光,陈炳为,陈阳美   

  1. 400010 重庆医科大学附属第二医院神经内科(张丽娜,刘雅婧,陈阳美);首都医科大学附属北京天坛医院神经内科(丁成赟);第三军医大学附属第一医院神经内科(史树贵);吉林大学第一医院神经内科(林卫红);昆明医学院第一附属医院神经内科(陈涛);四川省人民医院神经内科(孙红斌);南京大学医学院附属鼓楼医院神经内科(徐运);苏州大学附属第一医院神经内科(董万利);东南大学公共卫生学院(陈启光,陈炳为)
  • 出版日期:2011-08-16 发布日期:2012-04-30
  • 通讯作者: 陈阳美(Email:chenym1997@tom.com)

The efficacy and safety of zonisamide as adjunctive therapy in patients with partial seizure: a multicenter, randomized, double-blinded, placebo-controlled trial

ZHANG Lina, LIU Yajing, DING Chengyun, SHI Shugui, LIN Weihong, CHEN Tao, SUN Hongbin, XU Yun, DONG Wanli, CHEN Qiguang, CHEN Bingwei, CHEN Yangmei   

  1. Department of Neurology, the Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China
  • Online:2011-08-16 Published:2012-04-30
  • Contact: CHEN Yangmei (Email: chenym1997@tom.com)

摘要: 目的 观察唑尼沙胺分散片添加治疗部分性发作或继发全面性发作、全面性强直?阵挛发作及失神发作的疗效及安全性。方法 240 例诊断明确的部分性发作患者,被随机分为唑尼沙胺组(120 例)或对照组(120 例)。回顾性基线期(12 周)后,予初始剂量唑尼沙胺或安慰剂100 mg/次,1 次/d,3 周内递增至100 mg/次,3 次/d;分别在治疗第0、2、4、8 和16 周时进行随访,评价治疗第5 ~ 16 周时临床综合疗效的完全控制率和总有效率,以及药物安全性和不良反应。结果 治疗第5 ~ 16 周时,唑尼沙胺组患者癫痫完全控制率为34.04%(32/94)、总有效率74.47%(70/94),对照组分别为13.08%(14/107)和42.99%(46/107);两组临床综合疗效的完全控制率和总有效率比较,差异具有统计学意义(均P =0.000)。唑尼沙胺组患者常见药物不良反应包括食欲不振、嗜睡、疲劳、头晕、肝功能异常等,与对照组不良反应发生率比较差异有统计学意义(P = 0.003)。结论 唑尼沙胺作为添加药物治疗部分性发作或继发全面性发作、全面性强直-阵挛发作的疗效优于安慰剂,而且有较好的安全性和耐受性,是临床可以选择的新型抗癫痫药物之一。

关键词: 癫痫, 部分性, 药物疗法, 胺类, 随机对照试验

Abstract: Objective To evaluate the efficacy and safety of zonisamide (ZNS) as adjunctive therapy in patients with partial seizure or secondary generalized seizure, generalized tonic-clonic seizure (GTCS), absence seizure. Methods In this multicenter, randomized, double-blinded, placebo-controlled trial, 240 patients with confirmed partial seizure were randomly distributed to either ZNS group or placebo group. After a 12-week baseline period, all patients entered a 3-week titration interval, in which the ZNS dose gradually increased from 100mg qd to 100 mg tid, and a 13-week maintenance period. The main criteria of efficacy was measured by control rates and response rates during the period between the fifth week to the sixteenth week. The adverse effects were also counted for the evaluation of safety. Results Thirty-two patients (32/94, 34.04%) in ZNS group and 14 (14/107, 13.08%) in placebo group achieved complete control of seizure; 70 (70/94, 74.47%) in ZNS group and 46 (46/107, 42.99%) in placebo group had seizure frequency decreased by more than 50% , the rate differences were both statistically significant (P = 0.000, for all). The most common adverse effects included: decreased appetite, drowsiness, fatigue, dizziness, abnormal liver function, et al. The incidence of adverse effects in ZNS group was significantly lower than that in placebo group (P = 0.003). Conclusion Zonisamide for adjunctive therapy is superior to placebo in patients with partial seizure, and is generally well tolerated. It can be a new selective antiepileptic drug.

Key words: Epilepsies, partial, Drug therapy, Amines, Randomized controlled trial